RGNX REGENXBIO Inc.
Healthcare$6.31-0.63%ClosedMarket Cap: $326.2M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
15.79
P/S
3.74
EV/EBITDA
-1.63
DCF Value
$-23.87
FCF Yield
-72.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-0.1%
Operating Margin
-292.3%
Net Margin
-330.2%
ROE
-232.5%
ROA
-84.8%
ROIC
-92.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $6.4M | -73.2% | $-83.4M | $-90.1M | $— | — |
| Q4 null | $30.3M | 80.5% | $-57.6M | $-67.1M | $— | — |
| FY null | $170.4M | 88.1% | $-161.2M | $-193.9M | $— | — |
| Q3 null | $29.7M | -107.9% | $-52.4M | $-61.9M | $— | — |
| Q2 null | $21.4M | 57.3% | $-63.3M | $-70.9M | $— | — |
| Q1 null | $89.0M | 96.1% | $12.1M | $6.1M | $— | — |
| Q4 null | $21.2M | 70.2% | $-51.4M | $-51.2M | $— | — |
| FY null | $83.3M | 59.7% | $-233.3M | $-227.1M | $— | — |
| Q3 null | $24.2M | 48.8% | $-62.1M | $-59.6M | $— | — |
| Q2 null | $22.3M | 34.4% | $-56.0M | $-53.0M | $— | — |
| Q1 null | $15.6M | 45.8% | $-61.8M | $-63.3M | $— | — |
| Q4 2023 | $22.2M | 29.9% | $-63.9M | $-62.9M | $-1.43 | — |